JP2002511103A5 - - Google Patents

Download PDF

Info

Publication number
JP2002511103A5
JP2002511103A5 JP1999534939A JP53493999A JP2002511103A5 JP 2002511103 A5 JP2002511103 A5 JP 2002511103A5 JP 1999534939 A JP1999534939 A JP 1999534939A JP 53493999 A JP53493999 A JP 53493999A JP 2002511103 A5 JP2002511103 A5 JP 2002511103A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1999534939A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002511103A (ja
JP4353544B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1998/000288 external-priority patent/WO1999034822A1/en
Publication of JP2002511103A publication Critical patent/JP2002511103A/ja
Publication of JP2002511103A5 publication Critical patent/JP2002511103A5/ja
Application granted granted Critical
Publication of JP4353544B2 publication Critical patent/JP4353544B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP53493999A 1998-01-09 1998-01-09 アミリン作動薬ペプチド用製剤 Expired - Fee Related JP4353544B2 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1998/000288 WO1999034822A1 (en) 1998-01-09 1998-01-09 Formulations for amylin agonist peptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009058075A Division JP2009149684A (ja) 2009-03-11 2009-03-11 アミリン作動薬ペプチド用製剤

Publications (3)

Publication Number Publication Date
JP2002511103A JP2002511103A (ja) 2002-04-09
JP2002511103A5 true JP2002511103A5 (cg-RX-API-DMAC10.html) 2005-09-08
JP4353544B2 JP4353544B2 (ja) 2009-10-28

Family

ID=22266167

Family Applications (1)

Application Number Title Priority Date Filing Date
JP53493999A Expired - Fee Related JP4353544B2 (ja) 1998-01-09 1998-01-09 アミリン作動薬ペプチド用製剤

Country Status (9)

Country Link
EP (1) EP1044015B1 (cg-RX-API-DMAC10.html)
JP (1) JP4353544B2 (cg-RX-API-DMAC10.html)
AT (1) ATE410182T1 (cg-RX-API-DMAC10.html)
AU (1) AU760609B2 (cg-RX-API-DMAC10.html)
CA (1) CA2365742C (cg-RX-API-DMAC10.html)
DE (1) DE69840106D1 (cg-RX-API-DMAC10.html)
DK (1) DK1044015T3 (cg-RX-API-DMAC10.html)
ES (1) ES2316161T3 (cg-RX-API-DMAC10.html)
WO (1) WO1999034822A1 (cg-RX-API-DMAC10.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69740096D1 (de) 1996-08-08 2011-02-17 Amylin Pharmaceuticals Inc Pharmazeutische Zusammensetzung mit einem Exendin-4-Peptid
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
US7312196B2 (en) * 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
JP4647736B2 (ja) * 1999-09-30 2011-03-09 小林製薬株式会社 薬剤発散具
EP2036539A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Stable formulations of amylin and its analogues
CN101822822A (zh) * 2009-03-04 2010-09-08 北京德众万全药物技术开发有限公司 一种普兰林肽的药物组合物及其制备方法
JP2009149684A (ja) * 2009-03-11 2009-07-09 Amylin Pharmaceut Inc アミリン作動薬ペプチド用製剤
CN102145164B (zh) * 2010-12-16 2013-02-27 深圳市健元医药科技有限公司 一种更加稳定的iapp类似物注射剂
US9399065B2 (en) 2012-04-16 2016-07-26 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and injection site pain of insulin
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
HUE035803T2 (en) 2012-12-21 2018-05-28 Sanofi Sa Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重glp-1/升糖素受體促效劑
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自exendin-4之雙重glp-1/升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
WO2015168488A2 (en) 2014-05-02 2015-11-05 The Research Foundation For The State University Of New York Islet amyloid polypeptides with improved solubility
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物
CN107952064B (zh) * 2016-10-14 2023-10-20 江苏豪森药业集团有限公司 含有聚乙二醇洛塞那肽的药物制剂及其制备方法
EP3562500B1 (fr) * 2016-12-27 2023-07-19 Adocia Compositions sous forme de solution aqueuse injectable comprenant de l'amyline, un agoniste au récepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
WO2018144671A1 (en) 2017-02-01 2018-08-09 The Research Foundation For The State University Of New York Mutant islet amyloid polypeptides with improved solubility and methods for using the same
BR112020002804A2 (pt) 2017-08-24 2020-07-28 Novo Nordisk A/S composição farmacêutica líquida, e, kit
US11110063B2 (en) 2017-08-25 2021-09-07 MAIA Pharmaceuticals, Inc. Storage stable sincalide formulations
IL294521A (en) 2020-02-18 2022-09-01 Novo Nordisk As glp-1 compounds and their uses
AU2021399904B2 (en) * 2020-12-16 2024-09-05 Zealand Pharma A/S Pharmaceutical composition of glp-1/glp-2 dual agonists
IL312600B2 (en) 2022-05-30 2025-12-01 Zealand Pharma As Liquid formulations of amylin analogs

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4654324A (en) * 1981-08-27 1987-03-31 Eli Lilly And Company Human proinsulin pharmaceutical formulations
US5321008A (en) * 1991-01-10 1994-06-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions
EP0567626B1 (en) * 1991-11-19 2001-09-19 Amylin Pharmaceuticals, Inc. Amylin agonist peptides and uses therefor
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
US7910548B2 (en) * 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity

Similar Documents

Publication Publication Date Title
JP2000507042A5 (cg-RX-API-DMAC10.html)
JP2001520565A5 (cg-RX-API-DMAC10.html)
JP2000510751A5 (cg-RX-API-DMAC10.html)
JP2000509637A5 (cg-RX-API-DMAC10.html)
JP2000509942A5 (cg-RX-API-DMAC10.html)
JP2000509912A5 (cg-RX-API-DMAC10.html)
JP2001524983A5 (cg-RX-API-DMAC10.html)
JP2000509635A5 (cg-RX-API-DMAC10.html)
JP2001513776A5 (cg-RX-API-DMAC10.html)
JP2002502379A5 (cg-RX-API-DMAC10.html)
JP2001515380A5 (cg-RX-API-DMAC10.html)
JP2000509587A5 (cg-RX-API-DMAC10.html)
JP2000507369A5 (cg-RX-API-DMAC10.html)
JP2000510793A5 (cg-RX-API-DMAC10.html)
JP2000508022A5 (cg-RX-API-DMAC10.html)
JP2000508841A5 (cg-RX-API-DMAC10.html)
JP2000508680A5 (cg-RX-API-DMAC10.html)
JP2002500761A5 (cg-RX-API-DMAC10.html)
JP2002501377A5 (cg-RX-API-DMAC10.html)
JP2000509804A5 (cg-RX-API-DMAC10.html)
JP2000509755A5 (cg-RX-API-DMAC10.html)
JP2001517373A5 (cg-RX-API-DMAC10.html)
JP2000510969A5 (cg-RX-API-DMAC10.html)
JP2000510247A5 (cg-RX-API-DMAC10.html)
JP2000508102A5 (cg-RX-API-DMAC10.html)